Takeda's Orexin Agonist Orzeyful Gets FDA Approval, Eyes Broader CNS U

Takeda secured FDA clearance for Orzeyful, the first orexin‑based therapy for type‑1 narcolepsy, and experts see potential expansion into arousal, cognition and fatigue treatments.

Competition among orexin agonists is intensifying as developers aim to extend their use beyond narcolepsy into broader arousal, cognition and fatigue indications. In August, Takeda obtained FDA approval for its orexin agonist, marketed as Orzeyful (오제이풀). The drug is the first therapy to directly target the underlying biology of type‑1 narcolepsy. Industry experts believe the therapeutic potential of orexin analogues is not limited to sleep disorders; some have dubbed orexin the "neuroscience GLP‑1." Luis de Lecea, co‑discoverer of orexin and professor at Stanford University, highlighted the relevance of orexin modulation for attention and alertness, suggesting a wider clinical horizon.

Takeda's Orexin Agonist Orzeyful Receives FDA Approval, Targets Narcolepsy and Beyond

평점

평가 남기기

더 많은 기사